<rss version="2.0">
	<channel>
		<title>Frédéric Joliot Institute for Life Sciences - Sur le même thème</title>
		<link>https://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2025/Transport-trastuzumab-nanoparticles-nasal-epithelium.aspx</link>
		<description>Website of the Frédéric-Joliot Institute of Life Sciences which includes 4 departments: I2BC, DMTS, NeuroSpin and Service hospitalier Frédéric Joliot (SHFJ). The teams are mainly located at the CEA Paris-Saclay center and at the Orsay hospital. </description>
		<language>en-US</language>
		<image>
			<url>https://www.cea.fr/Style%20Library/Themes/drf/instituts/images/logo-cea-joliot-2023.png</url>
			<title>Frédéric Joliot Institute for Life Sciences - Sur le même thème</title>
			<link>https://joliot.cea.fr/drf/joliot/en</link>
		</image>

			<item>
				<title>Toward CAR-macrophage-based cellular immunotherapy for treating certain solid tumors?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2026/CAR-macrophages-cancers-solides.aspx</link>
				<description>Researchers from our DMTS department have published a study providing the first proof of concept for a CAR-macrophage therapy targeting the endothelin B receptor, which is overexpressed in melanoma cells.</description>
				<category domain="thematiques">Immune system ; Cancer ; Diagnosis and innovative treatment</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SPI</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2026/GettyImages-1317697228-vignette.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Seismic-wave physics for diagnosing brain tumors with passive MRI elastography</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Cerebral-tumour-diagnosis-passive-elastography.aspx</link>
				<description>Researchers at SHFJ and NeuroSpin applied a passive MRI elastography sequence to patients with brain tumors. This non-invasive approach provided information on tumor stiffness and nature, and could support early detection, surgical planning, and treatment monitoring.</description>
				<category domain="thematiques">Medical imaging ; MRI ; Cancer ; Brain</category>
				<category domain="public"></category>
				<category domain="organisation">Neurospin</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 26 Nov 2025 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Gennisson-pMRE-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Proof of concept for the passage of trastuzumab formulated in nanoparticles through an in vitro-reconstituted nasal epithelium.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Transport-trastuzumab-nanoparticles-nasal-epithelium.aspx</link>
				<description>​Researchers from SPI (DMTS) developed a formulation of PLGA nanoparticles loaded with the anticancer trastuzumab (NP-TZB) and measured their ability to cross a cellular model of the nasal epithelial barrier. This first validated step supports a potential nose-to-brain (N2B) delivery route.</description>
				<category domain="thematiques">Nanomedicine ; Cancer ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation">SPI</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 12 Nov 2025 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/NP-PLGA-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Cyanine 5-huwentoxin-IV : a new imaging agent for non-small cell lung cancer ?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Cyanine-5-huwentoxin-IV-imaging-agent-lung-cancer.aspx</link>
				<description>A team from SIMoS (DMTS) has demonstrated the ability of a peptide derived from a spider venom toxin to detect overexpressed sodium channels in a metastatic non-small cell lung cancer (NSCLC) cell line.</description>
				<category domain="thematiques">Biotechnology ; Biomarkers ; Cell and molecular imaging ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 10 Nov 2025 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Servent-Huwentoxin-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>PET imaging of OATP transporter-mediated drug elimination: impacts of sex and age</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/PET-imaging-OATP-function-impacts-sex-age.aspx</link>
				<description>Researchers from BioMaps (SHFJ) investigated the hepatic activity of organic anion-transporting polypeptides (OATPs), key players in the elimination of certain drugs, using a PET imaging approach with 11C-glyburide, which revealed differences in tracer pharmacokinetics between men and women.</description>
				<category domain="thematiques">Pharmacology ; Positron Emission Tomography ; Medical imaging</category>
				<category domain="public"></category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 15 Oct 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Tournier-OATP-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Développement de radioligands pour l’imagerie TEP de la neuroinflammation</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Radioligands-TEP-neuroinflammation.aspx</link>
				<description>Des chercheurs du SHFJ, en collaboration avec le CEA-Jacob, le CRN à Lyon et le PharmaCenter à Bonn ont imaginé, synthétisé et caractérisé deux radiotraceurs TEP ciblant P2Y12, une protéine impliquée dans l’activation de la microglie durant la neuroinflammation.​</description>
				<category domain="thematiques">Positron Emission Tomography ; Pharmacology</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">MIRcen</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">préclinique;modèle animal;</category>
				<pubDate>Fri, 03 Oct 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/P2Y12.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Mitosis: condense to better attach</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Mitose-KIF2C.aspx</link>
				<description>A study led by the I2BC shows that the formation of condensates of the enzyme KIF2C enables the concentration of two other proteins, PLK1 and phosphorylated BRCA2, on kinetochore microtubules during mitosis. This would serve to control chromosome alignment on the spindle and contribute to their stability.</description>
				<category domain="thematiques">DNA ; Structural biology ; Cancer</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SB2SM</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 08 Sep 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/KIF2-Kinetochore.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Ultrasound to counteract the cerebral effects of exposure to a neurotoxic agent</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Ultrasound-counter-exposure-neurotoxic-agent.aspx</link>
				<description>Researchers from BioMaps (SHFJ), NeuroSpin, and the french IRBA developed an innovative approach using focused ultrasound to improve brain delivery of an antidote, oxime, following exposure to an organophosphorus neurotoxic agent in a murine model.</description>
				<category domain="thematiques">Pharmacology ; Toxicology ; Brain ; CBRN-E threats</category>
				<category domain="public"></category>
				<category domain="organisation">Neurospin</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">preclinic;animal models;</category>
				<pubDate>Thu, 28 Aug 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Novell-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Cancer : transformer la mertansine en prodrogue pour une chimiothérapie ciblée et moins toxique grâce à une approche théranostique.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Cancer-mertansine-prodrogue.aspx</link>
				<description>Une équipe du laboratoire BioMaps, en collaboration avec l’Institut Galien Paris-Saclay a mis au point une stratégie innovante associant une prodrogue polymère et l&apos;imagerie par tomographie par émission de positons (TEP) pour améliorer l&apos;efficacité de la mertansine, un agent antitumoral puissant mais toxique. </description>
				<category domain="thematiques">Medical imaging ; Diagnosis and innovative treatment ; Cancer</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords">préclinique;modèle animal;</category>
				<pubDate>Tue, 01 Jul 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Mertansine-figure.png?RenditionID=6" type="image/png"></enclosure>
			</item>

			<item>
				<title>A promising drug candidate for the treatment of neonatal hypoxic-ischemic encephalopathy</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Drug-candidate-for-treatment-neonatal-encephalopathy.aspx</link>
				<description>Researchers from the SPI (DMTS) and the Women &amp; Infants Hospital in Providence have laid the molecular basis for the neuroprotection of a purine derivative in a preclinical model of neonatal hypoxic-ischemic encephalopathy (HIE). The promising results support the development of this drug candidate to treat HIE in neonates.</description>
				<category domain="thematiques">Pharmacology ; Brain ; Molecular mechanisms ; Diseases</category>
				<category domain="public"></category>
				<category domain="organisation">SPI</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">animal models;preclinic;</category>
				<pubDate>Thu, 26 Jun 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Mabondzo-EHI-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Theranostic antibodies targeting endothelin receptors in preclinical models of glioblastoma and melanoma</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Theranostic-antibodies-endothelin-receptors-models-glioblastoma-melanoma.aspx</link>
				<description>Researchers from SPI (DMTS) propose immunodiagnostic and immunotherapeutic approaches based on the use of innovative antibodies targeting two subtypes of endothelin receptors (ETA and ETB), recognised as relevant therapeutic targets in oncology.</description>
				<category domain="thematiques">Health ＆ life sciences ; Cancer ; Medical imaging ; Positron Emission Tomography</category>
				<category domain="public"></category>
				<category domain="organisation">Neurospin</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">preclinical research;animal models;</category>
				<pubDate>Thu, 22 May 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Boquet-Truillet-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Synthesis of an anti-cancer drug in living cells using micelle-based nanoreactors</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Synthesis-anti-cancer-drug-cells-using-nanomicelles.aspx</link>
				<description>A team at SCBM (DMTS) has designed nanomicelles that can be activated by a bioorthogonal reaction releasing a first chemical species, which then reacts with a second compound encapsulated in the micelles. Application to the synthesis of an anti-cancer drug, sorafenib, inside living cells. </description>
				<category domain="thematiques">Chemistry ; Methodologies for life sciences ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation">SCBM</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Fri, 11 Apr 2025 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Taran-Angew-Nanoreactor-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Immunological profiling of cancer : when click-chemistry meets mass spectrometry</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2025/Cancer-immunoprofiling-click-chemistry-mass-spectrometry.aspx</link>
				<description>Researchers at DMTS and SHFJ have carried out a multiplexed analysis of tumor cells and tissues, based on the use of cleavable therapeutic antibodies carrying mass tags, for the identification and quantification of cancer biomarkers. A proof-of-concept demonstrating the high potential of this tumor immunoprofiling approach</description>
				<category domain="thematiques">Cancer ; Chemistry ; Mass spectrometry ; Diagnosis</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">preclinical research;animal models;</category>
				<pubDate>Mon, 13 Jan 2025 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2025/Taran-ChemSci-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Micelles : comment améliorer l’efficacité radiothérapeutique lorsque les tumeurs résistent ?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/Micelles-efficacite-radiotherapeutique-tumeurs-radioresistantes.aspx</link>
				<description>​Des équipes du SCBM et du SHFJ, en collaboration avec le CEA-Jacob et l’ISMO ont développé une micelle perfluorée biocompatible pour améliorer l’efficacité des radiothérapies et qui serait particulièrement intéressante dans des environnements tumoraux radiorésistants.</description>
				<category domain="thematiques">Diagnosis and innovative treatment ; Cancer</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SCBM</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords">Cancer;préclinique;théranostique;modèle animal;</category>
				<pubDate>Wed, 23 Oct 2024 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2024/Micelles_carrousel_Godel-Pastre.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>PET imaging evaluation of the central effects of a drug-candidate to aid smoking cessation</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/PET-monitoring-central-effects-innovative-smoking-cessation-therapy.aspx</link>
				<description>A BioMaps team has used PET imaging to monitor glucose metabolism as a marker of the cerebral impact of smoking cessation, as well as the effects of a promising drug-candidate for the treatment of such cessation. By revealing the restoration of normal activity in the brain area associated with craving, these results offer hope for smoking cessation in humans</description>
				<category domain="thematiques">Positron Emission Tomography ; Medical imaging ; Pharmacology ; Brain</category>
				<category domain="public"></category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">Preclinical;animal models;murine model;</category>
				<pubDate>Thu, 29 Aug 2024 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2024/Goutal-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Nanosciences: Towards a new type of micellar phototherapy?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/phototherapy-micells.aspx</link>
				<description>SCBM researchers have designed nanometric micelles that can be activated by light and constructed by self-assembly of amphiphiles derived from ferrocene, which carries a hidden therapeutic activity in the absence of activation. </description>
				<category domain="thematiques">Chemistry ; Diagnosis and innovative treatment ; Nanomedicine</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SCBM</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 12 Jun 2024 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2024/PhototherapieMicellaire.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Response to intra-tumoral immunotherapy assessed by immunoPET in mice</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/Response-intra-tumoral-immunotherapy-by-immunoPET.aspx</link>
				<description>A team from BioMaps (SHFJ), in partnership with the Gustave Roussy Institute, has used immunoPET imaging to assess the influence of tissue distribution on the efficacy of cancer immunotherapy, administered intra-tumor and intravenously in mice. Intratumoral administration is more effective and reduces overall exposure of organs at risk</description>
				<category domain="thematiques">Medical imaging ; Positron Emission Tomography ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">preclinical research;animal models;</category>
				<pubDate>Fri, 19 Apr 2024 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2024/Truillet-Vignette-bis.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Nanometric micelles for targeted delivery of a prodrug against atherosclerosis</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/Nanomicelles-targeted-delivery-prodrug-atherosclerosis.aspx</link>
				<description>Teams from SCBM and SIMoS (DMTS) have developed nano-micelles for the vectorization of an active principle which regulates cholesterol metabolism towards atherosclerotic lesions.</description>
				<category domain="thematiques">Nanomedicine ; Diseases</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords">preclinic;animal models;</category>
				<pubDate>Thu, 14 Mar 2024 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2024/Micelle-Doris-Vignette.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Impact of metabolic variations on PET imaging of neuroinflammation in humans</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Impact-metabolism-PET-imaging-neuroinflammation.aspx</link>
				<description>Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation.</description>
				<category domain="thematiques">Positron Emission Tomography ; Medical imaging ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 12 Oct 2023 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2023/Peyronneau-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>PET imaging monitoring of an antibody targeting endothelin receptors expressed by glioblastoma tumors</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/PET-imaging-antibody-endothelin-receptors-glioblastoma-tumors.aspx</link>
				<description>Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.</description>
				<category domain="thematiques">Positron Emission Tomography ; Cancer ; Medical imaging</category>
				<category domain="public"></category>
				<category domain="organisation">Neurospin</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 07 Sep 2023 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2023/TruilletBoquet-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Identification of metabolomic signatures of high-grade breast tumors</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Metabolomic-signatures-high-grade-breast-tumors.aspx</link>
				<description>The TIRO laboratory of the SHFJ (Nice) identifies for the first time discriminating biomarkers of high-grade invasive breast tumors, using a non-targeted metabolomics approach performed on surgical specimens and cytoponctions from patients at different stages of malignancy.</description>
				<category domain="thematiques">Metabolomics ; Cancer ; Biomarkers</category>
				<category domain="public"></category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Fri, 04 Aug 2023 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2023/Pourcher-Vignette-CreativeDesignArt%20by%20GettyImages.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Radiomarquage du crizotinib au fluor-18 : un nouvel outil pour suivre par TEP la biodistribution de ce médicament</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Radiomarquage-crizotinib-fluor-18-nouvel-outil-TEP.aspx</link>
				<description>Des chercheurs du SHFJ ont mis au point la radiosynthèse au fluor-18 du crizotinib, un médicament qui ne pénètre pas dans le cerveau. Ce nouvel outil pour l’imagerie TEP permettra d’explorer de futures stratégies visant à faire passer la barrière hémato-encéphalique à ce médicament pour traiter certaines métastases cérébrales. </description>
				<category domain="thematiques">Positron Emission Tomography ; Cancer ; Diagnosis and innovative treatment</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 27 Apr 2023 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2023/Crizotinib-TEP-invivo.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>From a marine toxin to a melanocortin receptor antagonist, a therapeutic target for energy metabolism disorders</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Cone-marine-toxin-melanocortin-receptor-antagonist.aspx</link>
				<description>A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders</description>
				<category domain="thematiques">Pharmacology ; High-throughput screening ; Proteomics ; Transcriptomics</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 09 Feb 2023 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2023/NGilles-Conus-Vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Dual labeling and digital imaging for the evaluation of protein-drug conjugates in preclinical models</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/In-vivo-evaluation-antibody-drug-conjugate.aspx</link>
				<description>A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs.</description>
				<category domain="thematiques">Pharmacology ; Cell and molecular imaging</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 22 Aug 2022 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2022/Vignette-Devel.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>New radioligands for anti-PD-1/PD-L1 immunoPET </title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Radioligands-immunoPET-PD-1-PD-L1.aspx</link>
				<description>Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers. </description>
				<category domain="thematiques">Positron Emission Tomography ; Cancer</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">programmed cell death-ligand 1;</category>
				<pubDate>Tue, 12 Apr 2022 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2022/vignette_immunoTEP.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Buprenorphine/benzodiazepine interaction: why is it more dangerous?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Interaction-buprenorphine-benzodiazepine.aspx</link>
				<description>​A collaboration between the SHFJ and the UMR-S 1144 (University of Paris) shows that the deleterious effect of the buprenorphine/benzodiazepine combination would result from the combined action of each drug on its target.</description>
				<category domain="thematiques">Diagnosis and innovative treatment ; Pharmacology</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SHFJ</category>
				<category domain="typologie">Scientific result ; Article</category>
				<category domain="keywords">pharmacodynamics;opioids;</category>
				<pubDate>Fri, 25 Mar 2022 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2022/TEP-Buprenorphine_Diazepine-vignette.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Inhibiting autophagy: a new line to fight cellular senescence?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Autophagy-senescence.aspx</link>
				<description>Researchers from the Frédéric Joliot Institute have identified ouabain and chloroquine as two selective senolytic molecules that are effective in eliminating certain senescent cells. The study has been published in the journal Aging Cell.</description>
				<category domain="thematiques">Cancer ; Cellular mechanisms</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SCBM</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Tue, 15 Mar 2022 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2022/Strophanthus_gratus_Vignette_Tatiana-Gerus.jpg" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Deeptope: accelerating the development of therapeutic antibodies via high-throughput functional tests</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Institute/2021/Deeptope-start-up-Simos.aspx</link>
				<description>Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.</description>
				<category domain="thematiques">Biotechnology ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">News ; Article</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 29 Nov 2021 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_institutionnelles/2021/Vignette-Deeptope.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Multiparametric PET-MRI imaging: toward a biological characterization of tumors at the supervoxel level</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/PET-MRI-imaging-tumors-supervoxel-level.aspx</link>
				<description>A collaborative study led by BioMaps researchers (SHFJ) demonstrates that fully integrated quantitative multiparametric  analysis of non-small cell lung cancer in hybrid 18F-FDG PET/MRI 3T imaging is clinically feasible and could enable biological characterization of tumors at the supervoxel scale. </description>
				<category domain="thematiques">Medical imaging ; Positron Emission Tomography ; MRI ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 10 Nov 2021 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2021/Vignette-Besson-TEP-IRM.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Evaluation of the immunogenicity of peptide-drugs containing non-natural modifications</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/Immunogenicity-therapeutic-peptides.aspx</link>
				<description>A team from SIMoS (DMTS) in collaboration with Sanofi shows that the introduction of non-natural sequences into an immunogenic peptide attenuates the immune response against this peptide, an approach that could guide the design of less immunogenic, and therefore more effective, therapeutic peptides.</description>
				<category domain="thematiques">Health ＆ life sciences ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Tue, 01 Jun 2021 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2021/Vignette-LymphoT.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>PET imaging reveals the neuropharmacology of buprenorphine</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/PETimaging-neuropharmacology-buprenorphine.aspx</link>
				<description>Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).</description>
				<category domain="thematiques">Brain ; Positron Emission Tomography ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 05 May 2021 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2021/Vignette-BUP-Tournier.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>How works Mambalgin-1, an analgesic peptide from black mamba venom</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/How-works-Mambalgin-1.aspx</link>
				<description>Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.</description>
				<category domain="thematiques">Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 08 Apr 2021 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2021/Vignette-mamba-noir.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Anti-cancer therapeutic strategy: a chimera to inhibit ASF1</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/Foldamer-inhibitor-ASF1.aspx</link>
				<description>I2BC researchers, in collaboration with the European Institute of Chemistry and Biology (University of Bordeaux, CNRS), have developed a chimeric peptide/foldamer molecule that is resistant to proteolysis and inhibits ASF1, a potential target for anticancer treatment. The resolution of the structure of this chimera in interaction with its target, the first of its kind, reveals an unsuspected plasticity of the urea-based backbone that hugs the surface of ASF1. </description>
				<category domain="thematiques">Structural biology ; Molecular mechanisms ; Epigenetics ; Cancer</category>
				<category domain="public">Researchers</category>
				<category domain="organisation">SB2SM</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">NMR;radiocristallography;</category>
				<pubDate>Fri, 19 Mar 2021 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Science/2021/Asf1-ChimericInhibitor-vignette.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>A micellar probe for fluorine magnetic resonance tumor imaging</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/Micellar-probe-fluorine-MRI-tumor.aspx</link>
				<description>A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.</description>
				<category domain="thematiques">Chemistry ; Nanomedicine ; Cancer ; MRI</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 04 Mar 2021 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2021/Vignette-micelle-fluor-Ang.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Permeabilizing the blood-brain barrier to deliver therapeutic antibodies into the brain? ImmunoPET imaging provides answers</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/ImmunoPET-BBB-Ab.aspx</link>
				<description>Researchers from SHFJ, NeuroSpin and DMTS have demonstrated, by immunoPET imaging, the impact of transient BBB permeabilization on brain exposure to an anti-EGFR antibody. Promising prospects for targeted immunotherapy of glioblastoma.</description>
				<category domain="thematiques">Cancer ; Medical imaging ; Positron Emission Tomography</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">radiomarquage;zirconium;IRM;</category>
				<pubDate>Tue, 06 Oct 2020 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2020/Truillet_ImmunoTEP-AcEGFR_vignette.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>BRCA2 and breast cancer: a new mechanism revealed?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/BRCA2-breast-cancer.aspx</link>
				<description>​In a study conducted by a team from the Institut Curie, I2BC researchers have used their NMR know-how to study the phosphorylation of BRCA2 and  have thus contributed to revealing a mechanism potentially at the origin of chromosomal aberrations observed in breast BRCA2-mutated tumors.</description>
				<category domain="thematiques">Molecular mechanisms ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation">SB2SM</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">homologous recombination;Rad51;kinase;</category>
				<pubDate>Mon, 27 Apr 2020 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2020/Vignette_CharlotteMartin_InstitutCurie.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Innovative approach to radiolabel peptides with fluorine-18 for PET imaging</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/Innovative-approach-radiolabel-peptides-fluorine-18-PET-imaging.aspx</link>
				<description>Radiochemists from the BioMaps unit (SHFJ) have developed and automated a new fluor-18 radiolabelling method for peptides used to characterize specific pathological molecular signatures and thus target treatments. Peptides were conjugated to a specific tag, then radiolabeled in a single step under mild conditions, making this approach an innovative solution for PET imaging of peptides labeled with fluorine-18.</description>
				<category domain="thematiques">Chemistry ; Positron Emission Tomography ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 17 Feb 2020 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2020/Vignette-TEP-SHFJ[1].jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Glucocorticoids: a better evaluation of their effects in specific cancers?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/Glucocorticoids-better-evaluation-effect-cancers.aspx</link>
				<description>Senescence specialists (SBIGEM), in collaboration with the SCBM and the CNRGH (Jacob Institute), show that glucocorticoids can delay or even short-circuit it and disrupt its function as a tumor suppressor.</description>
				<category domain="thematiques">Cellular mechanisms ; Molecular mechanisms ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation">Fontenay-aux-Roses</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">MEK/ERK;oncogenesis;Senescence;</category>
				<pubDate>Mon, 09 Sep 2019 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/Melanoma_NationalCancerInstitute.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>A new biomarker to predict tumor progression from whole body PET images.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/New-prediction-biomarker-tumor-progression-PET-images.aspx</link>
				<description>The SHFJ/IMIV laboratory (Inserm 1023/CNRS/CEA/UP-Sud), in collaboration with hospital-university teams, has shown that, in patients with advanced-stage large cell lymphoma (B type), automatic quantitative measurements of tumor dissemination detected by whole-body PET imaging have a predictive value of progression-free survival (tumor stabilization) and overall survival.</description>
				<category domain="thematiques">Medical imaging ; Positron Emission Tomography ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Tue, 16 Jul 2019 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/Vignette-TEP-SHFJ.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>A new generation of nanovectors for anticancer therapies.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/New-nanovectors-anticancer-therapies.aspx</link>
				<description>As part of a collaboration with MIRCen (Jacob Institute), researchers of SCBM have developed functional micellar vectors that can effectively target tumors and whose therapeutic activity is intrinsically carried by the constitutive unit of the micelle. This combination leads to better drug load and avoids premature drug release.</description>
				<category domain="thematiques">Chemistry ; Nanosciences ; Nanomedicine</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 12 Jun 2019 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/Vignette-micelle-Doris.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>A promising therapeutic innovation for creatine transporter deficiency.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/therapeutic-innovation-creatine-transporter-deficiency.aspx</link>
				<description>​Two teams from JOLIOT (SPI / SCBM), in collaboration with the University of Cincinnati, confirm the interest of a drug candidate to treat the congenital creatine deficiency syndrome, a rare neurological childhood disease, responsible for developmental delays and intellectual disability. The results obtained in an animal model of the disease show that it is possible to administer, nasally, dodecyl creatine ester-loaded microspheres, thus improving the cognitive functions of treated animals.</description>
				<category domain="thematiques">Genetic diseases ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Fri, 17 May 2019 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/vignette-mabondzo.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>« Click and Release » chemistry for the targeted delivery of drugs in vivo</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/Click-Release-chemistry-targeted-delivery-drug-invivo.aspx</link>
				<description>A team from the SCBM, in collaboration with the SPI, the IC2MP and the University Hospital of Poitiers, has developed a bioorthogonal chemistry strategy that allows, in vivo, the controlled release of active ingredients contained in micelles-targeting cancerous tumors. These results pave the way for new strategies for targeted drug delivery.</description>
				<category domain="thematiques">Chemistry ; Cancer ; Nanomedicine</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Fri, 15 Mar 2019 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/vignette%20taran.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Pain: a promising toxin isolated from a spider venom</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/pain-promising-toxin-spider-venom.aspx</link>
				<description>A collaboration between SIMOPRO, Sanofi R &amp; D, Smartox Laboratories and the Thorax Institute, has isolated a toxin with antinociceptive properties from a high-throughput electrophysiological screening of a collection of more than 100 venoms. Cyriotoxin-1a has been identified, sequenced, chemically synthesized and functionally characterized - from cell to organism in vivo.</description>
				<category domain="thematiques">Pharmacology ; High-throughput screening</category>
				<category domain="public"></category>
				<category domain="organisation">SIMOPRO</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">antinociception;venoms;sodium channel;Pain;</category>
				<pubDate>Mon, 11 Mar 2019 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/Cyriopagopusschioedtei_Geichhorn2000.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Towards a better detection of glioblastoma infiltration</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/Towards-better-detection-glioblastoma-infiltration.aspx</link>
				<description>Glioblastoma is a very aggressive cancer of the central nervous system, mainly because of its ability to infiltrate the surrounding areas. A collaboration led by a team of SHFJ and involving NeuroSpin demonstrates the interest of two imaging techniques for the early detection of tumor infiltration.
</description>
				<category domain="thematiques">Cancer ; Medical imaging ; Positron Emission Tomography</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">PET imaging;glioblastoma;</category>
				<pubDate>Tue, 26 Feb 2019 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2019/Glioblastome_Inserm-Guichet_Pierre-Olivier.png" type="image/png"></enclosure>
			</item>

			<item>
				<title>Cerebral lymphoma: a new indication for [18F]Fludarabine?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/TEP-18FFludarabine-lymphome-cerebral.aspx</link>
				<description>A SHFJ research team (LDM-TEP, GIP Cyceron, Caen) has previously developed and produced a radiopharmaceutical, the [18F]-Fludarabine, to detect lymphomas using PET scan. The team has recently conducted a preclinical study that shows the molecule can help in diagnosis of cerebral lymphoma by differentiate it from glioblastoma, the main brain tumor. A clinical study should be launched before the end of the year.</description>
				<category domain="thematiques">Brain ; Medical imaging ; Cancer ; Diagnosis</category>
				<category domain="public"></category>
				<category domain="organisation">Joliot</category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords">FDG;lymphoma;glioblastoma;</category>
				<pubDate>Mon, 08 Oct 2018 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2018/vignette-camera_TEP_CT.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>What is the relationship between variants of the BRCA1 gene and susceptibility to cancer?</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/relationship-variants-BRCA1-cancer.aspx</link>
				<description>Research Teams from the Curie Institute, the Gustave Roussy Institute, as well as the biophysics teams from the Institute of Chemistry of Natural Substances and SB2SM (I2BC@Saclay) met to systematically identify structural defects and BRCA1 proteins encoded by variants of the BRCA1 gene, a gene predisposing to breast and ovarian cancer. Their results make it possible to propose a classification of these variants (neutral versus causal).</description>
				<category domain="thematiques">Cancer ; Structural biology ; DNA</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Fri, 28 Sep 2018 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2018/Vignette_Zinn_Brca1.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Functionalized micellar nanovectors for targeted tumor therapy</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/functionalized-micellar-nanovectors.aspx</link>
				<description>​As part of a collaboration with MIRCen (Institute of Biology François Jacob) and SBIGeM, SCBM researchers have developed functional micellar nanovectors capable of targeting a population of cancer cells.
</description>
				<category domain="thematiques">Chemistry ; Cancer</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Thu, 12 Apr 2018 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2018/vignette.png?RenditionID=5" type="image/png"></enclosure>
			</item>

			<item>
				<title>Ultrasound to improve drug delivery to the brain</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/ultrasound-drug-delivery-brain.aspx</link>
				<description>Researchers from NeuroSpin (Frédéric Joliot Institute/CEA) and MIRCen (François Jacob Institute/CEA Institute of Biology) have just developed an ultrasound device guided by magnetic resonance imaging (MRI) to increase temporarily and locally the vascular permeability in non-human primates, which could be used to effectively deliver drugs to the brain.</description>
				<category domain="thematiques">Brain ; Health ＆ life sciences ; Pharmacology</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 19 Feb 2018 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2018/Blood_Brain_Barriere_BenBrahimMohammed_Red.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>[18F] Fludarabine, a hope for lymphoma imaging</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/News/Science_news/2017/fludarabine_hope.aspx</link>
				<description>A Research Team of the SHFJ (LDM-TEP) has just developed an innovative radiopharmaceutical for lymphoproliferative diseases, [18F] Fludarabine.</description>
				<category domain="thematiques">Cancer ; Medical imaging</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 29 May 2017 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2017/camera_TEP_CT.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Pierre Fabre and H-Immune: a strategic research partnership for the development of immunotherapies in the field of cancer.</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Institute/2017/Pierre_fabre_h_immune.aspx</link>
				<description>​After its creation by Michel Léonetti, a researcher at SPI / LERI, and Luc Boblet, external holder at the CEA, backed by the IDEX Paris-Saclay funding among other things, the H-Immune start-up recently signed a partnership agreement with the Pierre Fabre Innovation Fund to develop cancer immunotherapy treatments.
</description>
				<category domain="thematiques">Cancer ; Institutional</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">News</category>
				<category domain="keywords"></category>
				<pubDate>Wed, 03 May 2017 10:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_institutionnelles/2017/Vignette_Leonetti.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>

			<item>
				<title>Monitoring hadrontherapy to improve patient safety</title>
				<link>https://www.cea.fr/drf/joliot/en/Pages/news/Science/2017/Monitoring_hadrontherapy_to_improve_patient_safety.aspx</link>
				<description>Evaluating the biological impact of hadrontherapy in healthy tissue upstream of a tumor is essential to assess the risk of radiation-induced sequelae. In the treatment of bone tumors, healthy articular cartilages are present in the path of the carbon ion beams. The development of 3D models has enabled IRCM&apos;s LARIA Research Team, in collaboration with IRAMIS and IBITECS (SBIGeM), to have relevant evaluation systems for these tissues.</description>
				<category domain="thematiques">Cancer ; Health ＆ life sciences</category>
				<category domain="public"></category>
				<category domain="organisation"></category>
				<category domain="typologie">Scientific result</category>
				<category domain="keywords"></category>
				<pubDate>Mon, 13 Mar 2017 11:00:00 GMT</pubDate>
				<enclosure url="https://joliot.cea.fr/drf/joliot/PublishingImages/Actualites/Actualites/Actualites_scientifiques/2017/cancer-cells-541954_1280.jpg?RenditionID=5" type="image/jpg"></enclosure>
			</item>
	</channel>
</rss>
